Aileron Cost Of Revenue from 2010 to 2024

ALRN Stock  USD 2.47  0.11  4.26%   
Aileron Therapeutics Cost Of Revenue yearly trend continues to be very stable with very little volatility. Cost Of Revenue is likely to drop to about 113 K. During the period from 2010 to 2024, Aileron Therapeutics Cost Of Revenue quarterly data regression pattern had sample variance of 35.8 T and median of  9,331,000. View All Fundamentals
 
Cost Of Revenue  
First Reported
2015-12-31
Previous Quarter
59 K
Current Value
K
Quarterly Volatility
3.9 M
 
Yuan Drop
 
Covid
Check Aileron Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aileron Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 384 K, Selling General Administrative of 10.4 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.14, Dividend Yield of 0.0 or PTB Ratio of 2.14. Aileron financial statements analysis is a perfect complement when working with Aileron Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Aileron Therapeutics Correlation against competitors.
To learn how to invest in Aileron Stock, please use our How to Invest in Aileron Therapeutics guide.

Latest Aileron Therapeutics' Cost Of Revenue Growth Pattern

Below is the plot of the Cost Of Revenue of Aileron Therapeutics over the last few years. Cost of Revenue is found on Aileron Therapeutics income statement and represents the costs associated with goods and services Aileron Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities. It is Aileron Therapeutics' Cost Of Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aileron Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Cost Of Revenue10 Years Trend
Slightly volatile
   Cost Of Revenue   
       Timeline  

Aileron Cost Of Revenue Regression Statistics

Arithmetic Mean6,552,670
Geometric Mean1,852,614
Coefficient Of Variation91.33
Mean Deviation5,130,129
Median9,331,000
Standard Deviation5,984,566
Sample Variance35.8T
Range18.3M
R-Value(0.63)
Mean Square Error23.1T
R-Squared0.40
Significance0.01
Slope(846,906)
Total Sum of Squares501.4T

Aileron Cost Of Revenue History

2024113 K
2023119 K
2022169 K
2021121 K
2020163 K
2019155 K
201818.4 M

About Aileron Therapeutics Financial Statements

Aileron Therapeutics investors utilize fundamental indicators, such as Cost Of Revenue, to predict how Aileron Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Cost Of Revenue119 K113 K

Pair Trading with Aileron Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aileron Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aileron Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Aileron Stock

  0.65BACK IMAC HoldingsPairCorr
  0.55VALN Valneva SE ADRPairCorr
  0.54MTEM Molecular TemplatesPairCorr
  0.54NKTX Nkarta IncPairCorr
  0.51CYRX CryoportPairCorr
The ability to find closely correlated positions to Aileron Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aileron Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aileron Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aileron Therapeutics to buy it.
The correlation of Aileron Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aileron Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aileron Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aileron Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Aileron Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aileron Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aileron Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aileron Therapeutics Stock:
Check out the analysis of Aileron Therapeutics Correlation against competitors.
To learn how to invest in Aileron Stock, please use our How to Invest in Aileron Therapeutics guide.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aileron Therapeutics. If investors know Aileron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aileron Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.88)
Return On Assets
(0.26)
Return On Equity
(0.44)
The market value of Aileron Therapeutics is measured differently than its book value, which is the value of Aileron that is recorded on the company's balance sheet. Investors also form their own opinion of Aileron Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aileron Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aileron Therapeutics' market value can be influenced by many factors that don't directly affect Aileron Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aileron Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aileron Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aileron Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.